LUPUS ERYTHEMATOSUS
Clinical trials for LUPUS ERYTHEMATOSUS explained in plain language.
Never miss a new study
Get alerted when new LUPUS ERYTHEMATOSUS trials appear
Sign up with your email to follow new studies for LUPUS ERYTHEMATOSUS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene-Edited immune cells aim to tame tough lupus
Disease control TerminatedThis study planned to test a single infusion of CB-010, a CRISPR-edited immune cell therapy, in people with severe lupus that did not respond to standard treatments. The goal was to see if it is safe and can control the disease. However, the study was withdrawn before any partici…
Matched conditions: LUPUS ERYTHEMATOSUS
Phase: PHASE1 • Sponsor: Caribou Biosciences, Inc. • Aim: Disease control
Last updated May 17, 2026 02:44 UTC
-
Engineered immune cells take on lupus and vasculitis in early trial
Disease control OngoingThis early-phase study tests a new treatment called SC291 for people with severe lupus or vasculitis that hasn't responded to standard therapies. SC291 uses specially engineered immune cells from a donor to target and destroy faulty B cells driving the disease. The main goal is t…
Matched conditions: LUPUS ERYTHEMATOSUS
Phase: PHASE1 • Sponsor: Sana Biotechnology • Aim: Disease control
Last updated May 11, 2026 20:50 UTC